Recent news and posts
MedTech-related health technology assessments from NIHR in March 2023
The National Institute for Health and Care Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance.
In March 2023, two MedTech-related assessments were published in the NIHR HTA Journal:
- Total ankle replacement versus ankle arthrodesis for patients aged 50 - 85 years with end-stage ankle osteoarthritis based on the pragmatic, multicenter, parallel-group, non-blinded randomized controlled trial (TARVA RCT). It was shown that both total ankle replacement and ankle fusion improved patients' walking ability. Still, there was no statistically significant difference between the treatment arms based on our primary outcome measure at one year. The implant most commonly used in the NHS (a fixed-bearing two-component implant) had better outcomes at one year than ankle fusion. Both total ankle replacement and ankle fusion appear to be safe. However, there were more wound-healing issues and nerve injuries in the total ankle replacement arm than in the ankle fusion arm. The total ankle replacement would be more likely cost-effective compared with ankle fusion;
- The feasibility of an RCT of techniques for managing an impacted fetal head during emergency caesarean section was evaluated in MIDAS scoping study. A proposed randomized controlled trial (RCT) would compare a new fetal pillow device with a long-established procedure, the vaginal push technique. It was concluded that such a trial would be widely supported by healthcare professionals and be feasible within the UK.
See the full details here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.